Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Prolactinomas and menopause: any changes in management?
Yona Greenman
*
*
Corresponding author for this work
Internal Medicine
Tel Aviv Sourasky Medical Center
Research output
:
Contribution to journal
›
Review article
›
peer-review
17
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Prolactinomas and menopause: any changes in management?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Menopause
100%
Change Management
100%
Prolactinoma
100%
Prolactin
50%
Hyperprolactinemia
50%
Medical Treatment
50%
Clinical Outcomes
25%
Dopamine Agonist
25%
Metabolic
25%
With Woman
25%
Postmenopausal Women
25%
Current Recommendations
25%
Treatment Goals
25%
Cancer Risk
25%
Current Guidelines
25%
Clinical Practice
25%
Withholding
25%
Literature Search
25%
Reproductive Season
25%
Agonist Treatment
25%
Tumor Mass
25%
Biological Behavior
25%
PubMed Database
25%
Current Management
25%
Healthy Postmenopausal Women
25%
Hypogonadism
25%
Medline Database
25%
Microadenoma
25%
Macroadenoma
25%
Macroprolactinoma
25%
Prolactin-secreting Adenoma
25%
Microprolactinoma
25%
Dopamine Agonist Withdrawal Syndrome
25%
Nursing and Health Professions
Prolactinoma
100%
Medline
28%
Combination Therapy
28%
Dopamine Receptor Stimulating Agent
28%
Prolactin
28%
Hyperprolactinemia
28%
Practice Guideline
14%
Clinical Outcome
14%
Malignant Neoplasm
14%
Clinical Practice
14%
Hypogonadism
14%
Cancer Control
14%
Macroadenoma
14%
Microadenoma
14%
Medicine and Dentistry
Prolactinoma
100%
Combination Therapy
28%
Postmenopause
28%
Prolactin
28%
Dopamine Agonist
28%
Hyperprolactinemia
28%
Malignant Neoplasm
14%
Cardiovascular System
14%
Neoplasm
14%
Hypogonadism
14%
Microadenoma
14%
Macroadenoma
14%
Pharmacology, Toxicology and Pharmaceutical Science
Prolactinoma
100%
Hyperprolactinemia
28%
Prolactin
28%
Dopamine Receptor Stimulating Agent
28%
Combination Therapy
28%
Malignant Neoplasm
14%
Neoplasm
14%
Hypogonadism
14%
Macroadenoma
14%
Microadenoma
14%